The Dermatology therapeutics market is growing at a rapid pace
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for  Nabiximols; Karyopharm’s Xpovio; Kiadis USD 358M Buyout
absssi-pipeline-analysis
Pharma Companies Foray into the ABSSS...

The introduction of antibiotics subsequently transformed the healthcare industry bringing on the table seve...

recent-pharma-biotech-lifescience-healthcare-news-updates-for-vertex-virta-kalvista-ovid-crispr-therapeutics
Vertex leads in CRISPR Therapeutics d...

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with...

Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta’s Kimyrsa
Merck, Gilead teams up for HIV treat...

Merck, Gilead  to co-develop combined HIV treatments Merck and Gilead have announced a collaboration t...

recent-pharma-biotech-news-updates-happenings-for-beam-grail-quest-diagnostics
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infan...

Beam adds to drug delivery stable with USD 120 Million GuideTx buyBeam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in t...


recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1...

Plaque psoriasis drug outshines the competition in phase III trialBristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setti...


Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio BuyoutHorizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pi...


Hallux-Valgus-market-therapeutics-therapies-epidemiology-pipeline
A Need for Curative Treatment Expected to Attract the Pharma Players in the Hallux Valgus Market ...

Hallux Valgus, also know as Bunion, is the most common forefoot problem in adults. It is the most common pathologic entity of the big toe. It refers to the progressive swelling of the soft tissue....


pharma happenings for BMS Sanofi GW Pharmaceuticals Kiadis
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyophar...

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's OtezlaBristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (a...


Epidermolysis-Bullosa-Market-size-share-trends-growth-forecast
Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size

Epidermolysis bullosa (EB) places a significant socioeconomic burden on patients. Several reports stated that Epidermolysis bullosa had a considerable negative impact on the quality of the lives o...


Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmo...

According to WHO, Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death g.....

Myelodysplastic Syndrome (MDS) Market Analysis
Myelodysplastic Syndrome ...

Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....

Prostate Cancer Market
Prostate Cancer...

Prostate Cancer is the second most common malignancy in men worldwide, after lung cancer. Most Prost.....

Editor's Pick
Healthcare Data Breach: What it Means for Companies and the Consumer?

Data and analytics today are playing a major role in the organization’s growth. Stakeho...

Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Co...

Onychomycosis is the most commonly prevalent nail infection in adults. It is a fungal i...

Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

The necessity of a robust Angelman syndrome pipeline is indispensable at the current mo...

The New Buzz of Transcranial Stimulation Devices in the Neurological Disorder...

Neurological disorders are one of the major causes of death and disability across the g...

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Maj...

As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million ...